RxDoctor Payments Data

Aaron Milam

Podiatrist · North Providence, RINPI 1104927441

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations.

$1,601in general payments, 2019–2025

Across 59 payments — averaging $27.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$250
  • Paratek Pharmaceuticals, Inc.$231
  • Kerecis Limited$158
  • Vertex$127
  • Osiris Therapeutics Inc.$118
  • Biotissue Holdings Inc.$108
  • plus $610 from 18 others

What the payments were for

  • Food & beverage$1,601100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,601 in reported general payments places this provider in the 80th percentile of 29 podiatrist providers in Rhode Island.

See all podiatrist providers in Rhode Island

Medicare billing

Part B allowed, 2024
$197,438
Medicare patients
689
Services billed
3,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.15$5,077
CiclopiroxCiclopirox Olamine180$3,122
Econazole Nitrate11$1,230
Ammonium Lactate43$814
Cephalexin91$747
Gabapentin53$684
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip42$609
Clotrimazole37$585
Oxycodone Hcl51$519
Allopurinol47$466
Ketoconazole24$431
Colchicine20$342
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$322
Methylprednisolone40$308
Mupirocin36$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$250$5,07715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 29 podiatrist providers in Rhode Island.

Other podiatrist in North Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →